Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18993241 | 0.76 | NOS1 (0.37) | NOS1AXLNPC1RAB9AGRM2 | |
| SCHEMBL20226439 | 0.76 | CYP11B1 (0.46) | NPC1RAB9A | |
| SCHEMBL1900443 | 0.76 | CCR4 (0.40) | NOS1AXLNPC1RAB9AGRM2 | |
| SCHEMBL29692488 | 0.76 | CCR4 (0.40) | NOS1AXLNPC1RAB9AGRM2 | |
| SCHEMBL28772690 | 0.73 | CCR1 (0.38) | NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL4112054 | 0.73 | SCN9A (0.41) | NOS1AXLNPC1RAB9AALDH1A1 | |
| SCHEMBL441028 | 0.72 | CYP1A2 (0.54) | ALDH1A1 | |
| SCHEMBL4126308 | 0.72 | MAPT (0.50) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL23652343 | 0.72 | NOS1 (0.34) | NOS1AXLNPC1RAB9AGRM2 | |
| SCHEMBL30975428 | 0.72 | EZH2 (0.39) | NOS1AXLNPC1RAB9AGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | ARAXES PHARMA LLC | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | TTBK2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TTBK1 | NOS1 2271/4885AXL 2848/4885NPC1 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.